cabozantinib

Overview

Cabozantinib is a small-molecule, multi-target tyrosine kinase inhibitor (TKI) that exerts its therapeutic effects primarily through inhibition of vascular endothelial growth factor receptors (VEGFRs), met (hepatocyte growth factor receptor), AXL, and RET, among other kinases. Originally developed by Exelixis and approved by the U.S. Food and Drug Administration, cabozantinib is clinically indicated for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma, and medullary thyroid cancer. By simultaneously blocking multiple oncogenic signaling axes — notably the VEGFR-driven angiogenesis pathway and the met pathway implicated in tumor invasiveness and resistance — cabozantinib disrupts tumor growth, metastatic spread, and immune evasion in a coordinated manner.

Beyond its established role in oncology, emerging research has begun to reveal previously unrecognized biological activities for cabozantinib, including modulation of innate immune cell death pathways. Its broad kinase inhibitory profile positions it as a candidate for drug repurposing, extending potential therapeutic applications into inflammatory and immune-mediated diseases.

Recent Publications Summary

Cabozantinib, a multi-target tyrosine kinase inhibitor, has been extensively evaluated for the treatment of advanced renal cell carcinoma (RCC) as both monotherapy and in combination regimens with immunotherapeutic agents. Clinical trials have demonstrated activity of the cabozantinib-nivolumab combination across diverse histologic subtypes of non-clear cell RCC, with an objective response rate of 45.2% and disease control rate of 93.6%, including responses across papillary, FH-deficient, and TFE3-rearranged tumors 42366526Jun. Real-world comparative effectiveness analyses have assessed cabozantinib plus nivolumab regimens alongside pembrolizumab plus lenvatinib, both established as effective first-line approaches for metastatic RCC 42204034May.

Clinical utility of cabozantinib has been demonstrated in specialized RCC populations. The phase II CABRAMET trial evaluated cabozantinib in RCC patients with non-locally pretreated brain metastases, providing prospective data on systemic treatment outcomes in this historically challenging clinical scenario 41946178Apr. Predictive biomarkers for treatment response represent an emerging research area; exploratory metabolic pathway analysis with clinical and in vitro samples identified serum metabolite signatures potentially capable of distinguishing cabozantinib responders from poor responders in advanced RCC 42538613Aug. Cabozantinib has also been investigated in combination with emerging targeted agents, with clinical trials currently evaluating casdatifan, a potent HIF-2α inhibitor, in combination with cabozantinib for advanced clear cell RCC 42246926Jun.

safety monitoring has revealed important adverse event profiles associated with cabozantinib therapy. A nine-year pharmacovigilance study documented the safety profile of cabozantinib in advanced RCC, including sex-specific adverse events and cardiovascular toxicity 42212588May. In immune-targeted combinations, distinct adverse event signals have been identified; atezolizumab plus cabozantinib regimens were associated with signals of gastrointestinal hemorrhage and malignant neoplasm progression 42461453Jul.

Beyond RCC, investigation has expanded cabozantinib applications to other malignancies and inflammatory conditions. In non-small cell lung cancer (NSCLC) harboring met fusion alterations with acquired resistance to type I met inhibitors, sequential treatment with cabozantinib, a type II met inhibitor, resulted in disease stabilization 42015375Apr. Mechanistic studies have additionally identified cabozantinib as an inhibitor of necroptosis through selective blocking of MLKL oligomerization; preclinical evidence in an imiquimod-induced psoriasis model demonstrated cabozantinib-mediated reduction of epidermal hyperplasia and inflammatory cytokine expression, highlighting therapeutic potential for drug repurposing in necroptosis-related inflammatory disorders 41747872Feb.

What Changes, What Holds

1. Cabozantinib now looks like a credible partner for immunotherapy in broader RCC subtypes, not just a monotherapy TKI
NEW DIRECTION Cabozantinib’s established RCC role is being extended into combination regimens that appear active across non-clear cell histologies, which broadens its practical use beyond the baseline’s general RCC indication. The comparative effectiveness work also suggests it belongs in the current first-line metastatic RCC landscape alongside other IO-TKI backbones, though it does not displace the overview’s core mechanism or approved uses. 42366526Jun42204034May

2. Cabozantinib’s RCC use is expanding into harder-to-treat settings, but response prediction remains unsettled
NEW DIRECTION Prospective data in brain-metastatic RCC and ongoing testing with a HIF-2α inhibitor extend the drug into specialized clinical scenarios not covered by the baseline, which already framed it as an established RCC therapy. The metabolite-signature work adds a possible way to sort responders from nonresponders, but that is still exploratory and does not yet change the baseline account of how the drug is used. 41946178Apr42538613Aug

3. safety signals now include cardiovascular and hemorrhagic concerns that need active monitoring in combination regimens
NEW DIRECTION Long-term pharmacovigilance sharpens the adverse-event profile of cabozantinib in advanced RCC, especially sex-specific effects and cardiovascular toxicity, while the atezolizumab combination signal raises additional concern for gastrointestinal bleeding and progression. None of this contradicts the baseline, which did not claim safety in these respects, but it does mean the drug’s real-world risk profile is broader and more regimen-dependent than the overview suggests. 42212588May42461453Jul

4. Cabozantinib is being repurposed as a resistance-bypassing met inhibitor and as a necroptosis blocker
NEW DIRECTION Sequential use after type I met inhibitor resistance in met-fusion NSCLC extends the baseline’s met-targeting story into a new clinical niche, showing a role in overcoming acquired resistance rather than only suppressing tumor signaling. The necroptosis/psoriasis findings go further by adding a non-oncologic anti-inflammatory mechanism that the overview did not cover at all, making repurposing a more concrete possibility than before. 42015375Apr41747872Feb

Overview update candidates: cabozantinib activity in non-clear cell RCC combinations; its place among first-line metastatic RCC regimens; cabozantinib in RCC with brain metastases; biomarker development for response prediction; combination with HIF-2α inhibition; cardiovascular toxicity; sex-specific adverse events; and hemorrhagic risk in some combinations; cabozantinib after acquired resistance to type I met inhibitors; MLKL-linked necroptosis inhibition and psoriasis-model activity.